Narrative review explores miRNA signalling versus conventional RNA therapeutics in metabolic dysfunction-associated steatotic liver disease

This source is a narrative review focusing on miRNA signalling within the context of metabolic dysfunction-associated steatotic liver disease. The publication compares this mechanism against conventional RNA-based therapeutics but does not report a specific study population, sample size, or setting. Consequently, no primary or secondary outcomes were quantified in this document.

The authors do not provide pooled effect sizes, p-values, confidence intervals, or adverse event rates. Safety data, including tolerability and discontinuations, were not reported. The review does not establish causality or provide specific follow-up durations.

Because key details such as the population, intervention specifics, and main results are not reported, the practice relevance is not defined. The authors acknowledge these gaps, noting that the evidence is currently incomplete for direct clinical application.

Readers should interpret these findings as a qualitative overview rather than quantitative evidence. The review highlights the theoretical comparison between miRNA signalling and standard RNA therapies without providing data to support specific clinical decisions.